Floatz logo

Pd-L1 T-Hank

Head and Neck Squamous Cell Carcinoma

ImmunityBio, Inc.Cell therapyPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

249 Active assets in the Head and Neck Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Akeso
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Akeso
Phase 3BB
Irinotecan
Neonc Technologies, Inc.
Phase 2BB
Tisotumab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2BB
Capecitabine
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

Pd-L1 T-Hank is also rated in:

cutaneous neuroendocrine carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Microsatellite InstabilityDormant
CCC
Indicative ·
53 / 100
View asset →
Mismatch Repair DeficiencyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →